The authors sought to understand the clinical and angiographic outcomes of dissections left after drug-coated balloon (DCB) angioplasty.
However, from the mechanical point of view, DCB behave just like simple balloons, thus they share some of the main limitations of these devices after angioplasty, namely coronary dissection and acute recoil.
Very preliminary observations seem to show how new-generation DCB could be associated with a faster spontaneous healing of an arterial dissection left after balloon angioplasty, especially in case of angioplasties of the femoropopliteal region and for the treatment of in-stent restenosis (6, 7) . The aim of this study was to test this hypothesis in a consecutive series of patients with native coronary vessel disease.
METHODS
This is an observational study conducted at 2 centers expert in DCB angioplasty. The aim of the study was to investigate the outcome of consecutive coronary dissections left after DCB angioplasty in native vessels.
Inclusion criterion was any percutaneous coronary intervention (PCI) performed with DCB in native coronary vessels. Exclusion criteria were any use of DCB for reasons different from the aforementioned (e.g., for in-stent restenosis); ST-segment elevation myocardial infarction that occurred in the previous 48 h; or life expectancy <1 year. Other clinical indications for PCI, unstable hemodynamics at presentation, and the presence of renal insufficiency were not exclusion criteria. We had a restrictive use of DCB in case of big vessel size (e.g., >3 mm in diameter) or in case of very calcific vessels, especially when we feared possible vessel recoil.
In the current study, the following devices were used: Restore (Cardionovum, Milano, Italy) and Elutax SV (Aachen Resonance, Lainate, Italy) DCB. These 2 devices, both eluting paclitaxel, may be considered a second-generation DCB because of a more efficient delivery of paclitaxel to the vessel wall, which results in a longer persistence of the drug. Restore DCB has a concentration of paclitaxel of 3.0 mg/mm 2 of balloon surface, and shellac is used as a carrier. Elutax SV DCB has a concentration of paclitaxel of 2.2 mg/mm 2 of balloon surface, and is embedded in a 3-layer matrix.
Available measures for both devices used in this study included diameters of 2.0, 2.5, and 3.0 mm, and lengths of 15, 20, 25 , and 30 mm.
The intervention was performed according to international guidelines and the recent Italian position paper on DCB PCI (8) . Specifically, pre-dilation with an undersized semicompliant balloon was mandatory (the recommended size was 0.9:1 of DCB). In case of flow-limiting dissection after pre-dilation, we recommended considering conversion to a stent PCI without using a DCB. The DCB was inflated for 30 to 45 s at nominal pressure, according to the morphological characteristics of the lesion (e.g., degree of calcification, length, tortuosity). After DCB use, final assessment was undertaken after at least 5 min, in order to catch early vessel recoil. In this event, bailout stent implantation was considered. The type of stent or scaffold was left to the operator's discretion. Cortese et al.
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LLL ¼ late lumen loss; other abbreviations as in Table 2 .
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 5 , 2 0 1 5
Cortese et al.
D E C E M B E R
2 8 , 2 0 1 5 : 2 0 0 3 -9
Coronary Drug-Coated Balloons and Dissection
For the purpose of this analysis, we studied the 52 patients that had an angiographically detectable dissection after DCB angioplasty. All patients of this cohort underwent programmed coronary angiography after 6 to 9 months. Baseline clinical characteristics and clinical indication to PCI of the entire population and of the 2 cohorts are shown in Table 1 .
The dissection study group did not differ significantly from the entire DCB group, if we exclude a higher incidence of left anterior descending artery as the culprit vessel, the degree of calcification of the culprit lesion, the size of balloon used for predilation, and the size of the DCB ( Table 2 ). Baseline angiographic characteristics are shown in Table 2 .
Of note, the vessel diameter was 2.83 mm in the entire population, and 2.80 mm in the dissection population.
Of the 52 patients with residual dissection after DCB PCI, 4 had a prosthesis implanted (2 a bare-metal stent, 1 a DES, and 1 a biovascular scaffold). The reason for implanting a stent/scaffold was impairment of distal flow in 3 patients, and the presence of a spiral, type D dissection in 1.
All patients with a final dissection underwent scheduled angiographic follow-up with quantitative coronary assessment, that was undertaken after 201 days (interquartile range 161 to 250 days). Angiographic outcome is presented in Table 3 . Of note, LLL was as low as 0.14 AE 0.28 mm in this group. We also observed a late lumen enlargement in the treated segments ( Figure 1) . A and B show the final dissections (respectively, a type C and a long type A dissection, red circles); after 6 months, both dissections were healed (C and D). DCB ¼ drug-coated balloon.
Cortese et al. were chronic. There was not an apparent correlation between the type of initial dissection left after DCB angioplasty and its fate. We followed the NHLBI classification for coronary dissections. DCB ¼ drug-coated balloon; NHLBI ¼ National Heart, Lung, and Blood Institute.
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CONCLUSIONS
In a consecutive series of patients treated with newgeneration DCB for native coronary artery disease and with a final non-flow-limiting dissection, these lesions tended to heal despite their initial severity.
After DCB angioplasty, a strategy of bailout stenting should be reserved to more severe, flow-limiting dissections.
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